HotStockMarket › Forums › HSM Stock Forum › Penny Stocks › DDSS - Labopharm Inc
New Posts  All Forums:Forum Nav:

DDSS - Labopharm Inc - Page 4

post #61 of 701
6/10/09 at 5:21pm
damnt are u kidding me ahah
Reply
Reply

Featured Stories on HotStockMarket

thinkorswim Trading platform
Mark's Weekly Trading Log
Stonerangers forum
post #62 of 701
6/10/09 at 5:24pm
that would happen too . w.e . got my buy in for 1.80 . hopefully it hits
Reply
Reply
post #63 of 701
6/10/09 at 10:33pm
Up to $2.35 AH.
Reply
Reply
post #64 of 701
6/10/09 at 10:43pm
Very nice glad I bought when I did. I've been doing my research on this one and it looks like they have a pretty good drug for depression.
Reply
Reply
post #65 of 701
6/11/09 at 2:30am
this is stock rising.

go go DDSS
Reply
Reply
post #66 of 701
6/13/09 at 1:31am
this one is on my radar..
Reply
Reply
post #67 of 701
6/16/09 at 2:32am
in DDSS @ 2.10
Reply
Reply
post #68 of 701
6/16/09 at 10:36pm
So you like this one tokyo?
Reply
Reply
post #69 of 701
6/17/09 at 12:33am
I really like the volume on DDSS lately. If this can continue to rise steadily until July 1, it should really get interesting closer to the FDA decision date.
Reply
Reply
post #70 of 701
6/17/09 at 5:41am
Quote:
Originally Posted by j4c View Post
So you like this one tokyo?
yes, only concern is that is close to its 52 week high (2.37), but if it can break, it should run hard.. 2.97 was the next high
Reply
Reply
post #71 of 701
6/17/09 at 5:43am
Quote:
Originally Posted by NYrunner View Post
I really like the volume on DDSS lately. If this can continue to rise steadily until July 1, it should really get interesting closer to the FDA decision date.
agree, 3-5% per day over the next 10 days can really add up, I would expect a pullback but all depends on where the $ is moving to.. TSPT, SVNT, ADLS, ISTA are all good plays also.
Reply
Reply
post #72 of 701
6/19/09 at 3:20pm
So the decision date is 7/18 which is a Saturday, so will we get word more likely on Monday?
Reply
Reply
post #73 of 701
6/20/09 at 6:58pm
Quote:
Originally Posted by j4c View Post
So the decision date is 7/18 which is a Saturday, so will we get word more likely on Monday?
If then. The FDA has been so late with their announcements, it wouldn't surprise me in the least if the decision comes several weeks late.
Reply
Reply
post #74 of 701
6/23/09 at 5:46am
maybe, but I hope not
Reply
Reply
post #75 of 701
6/23/09 at 1:52pm
Good morning DDSS shareholders . It's interesting to see that DDSS is still so low on volume the past few days. I don't know if anyone has mention this recently, but Labopharm have a presentation next week at the 49th NCDEU meeting to publicize their effectiveness of phase 3 clinical trial for trazodone. This was mentioned last month in one of their press release: http://www.labopharm.com/Default.asp...&reqId=1289981

I would like to see DDSS goes up as we wait for the PDUFA date .
Reply
Reply
post #76 of 701
6/24/09 at 7:46pm
nice so far today for DDSS, 2.25 right now.. hoping it could close about 2.25..
Reply
Reply
post #77 of 701
6/24/09 at 8:09pm
nice close.. 2.26.. now we need some volume as we get closer to 7/18 we should see that volume build.
Reply
Reply
post #78 of 701
6/25/09 at 12:22am
expecting to see this one creep up over the next few weeks
Reply
Reply
post #79 of 701
6/25/09 at 12:46am
There was an interesting spike in volume around 3pm that drove the price up. I wish I had the time to watch L2 quotes today. Does anyone know of a way to check out the orders placed during market hours after the end of the session? I would like to see the types of trades that were placed during the spike in volume.
Reply
Reply
post #80 of 701
6/25/09 at 11:22am

Labopharm amends debt facility agreement with Hercules

Company Improves Financial Flexibility

Quote:
LAVAL, QC, June 25 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today
announced it has amended its debt facility agreement with Hercules Technology
Growth Capital, Inc. (NASDAQ: HTGC).
Based on regulatory approval and recent launch of its once-daily tramadol
product in the United States, the Company has been able to establish more
favourable repayment terms. Under the amended agreement, Labopharm has
extended the date required to begin repaying the loan to July 1, 2010 from
July 1, 2009, and the maturity date of the loan has been extended to June 1,
2012 from December 1, 2011. In consideration of the revised repayment terms,
Labopharm will not draw down the remaining US$5 million of the US$25 million
facility.
The amended agreement provides Labopharm with greater financial
flexibility as the Company continues to transition to a commercial entity. The
amendments will result in lower interest expense in 2009 and will provide
additional liquidity through 2010 and 2011, strengthening the Company's
balance sheet as commercial sales of its once-daily tramadol product increase
following the recent U.S. launch. The remaining portion of the Warrant granted
to HTGC under the terms of the original agreement vested at the completion of
the amendment. All other terms of the agreement remain unchanged.
Labopharm also announced that it has entered into a $2.6 million credit
facility with the National Bank of Canada (the "ABCP Facility"). This
facility, which has a term of three years, is in furtherance of a previously
announced agreement with the National Bank of Canada to borrow an amount of up
to 45% of the principal value of the notes issued to the Company in the
context of the restructuring of the Canadian asset-backed commercial paper,
which amount the Company can, under certain conditions, repay at maturity by
delivering the notes to the bank.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing
small molecule drugs using its proprietary controlled-release technologies.
The Company's lead product, a unique once-daily formulation of tramadol, is
now available in 17 countries around the world, including the U.S., Canada,
major European markets, and Australia, among others. The Company's second
product, a novel formulation of trazodone for the treatment of major
depressive disorder, is under regulatory review by the FDA. The Company also
has a robust pipeline of follow-on products in both pre-clinical and clinical
development. Labopharm's vision is to become an integrated, international,
specialty pharmaceutical company with the capability to internally develop and
commercialize its own products. For more information, please visit
www.labopharm.com.

This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of factors,
including the uncertainties related to the regulatory process in various
countries for the approval of the Company's products and the successful
commercialization of the products throughout the world if they are approved.
Investors should consult the Company's ongoing quarterly filings and annual
reports for additional information on risks and uncertainties relating to
these forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. The Company disclaims any obligation to update
these forward-looking statements.


Awesome! I wonder if the sudden spike in volume around 3pm yesterday had something to do with this PR.
Reply
Reply
New Posts  All Forums:Forum Nav:
  Return Home
  Back to Forum: Penny Stocks

Featured Stories on HotStockMarket

thinkorswim Trading platform
Mark's Weekly Trading Log
Stonerangers forum
HotStockMarket › Forums › HSM Stock Forum › Penny Stocks › DDSS - Labopharm Inc